Anteris Technologies Global Corp - Asset Resilience Ratio
Anteris Technologies Global Corp (AVR) has an Asset Resilience Ratio of 33.27% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how liquid is Anteris Technologies Global Corp's working capital to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2010–2024)
This chart shows how Anteris Technologies Global Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Anteris Technologies Global Corp.
Liquid Assets Composition Over Time
This chart breaks down Anteris Technologies Global Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Anteris Technologies Global Corp (AVR) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 0% |
| Short-term Investments | AU$43.38 Million | 33.27% |
| Total Liquid Assets | AU$43.38 Million | 33.27% |
Asset Resilience Insights
- Very High Liquidity: Anteris Technologies Global Corp maintains exceptional liquid asset reserves at 33.27% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Anteris Technologies Global Corp Industry Peers by Asset Resilience Ratio
Compare Anteris Technologies Global Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
TransMedics Group Inc
NASDAQ:TMDX |
Medical Devices | 0.00% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Hangzhou AGS MedTech Co. Ltd. A
SHG:688581 |
Medical Devices | 18.80% |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580 |
Medical Devices | 10.74% |
|
Nanjing Medlander Medical Technology Co. Ltd. A
SHG:688273 |
Medical Devices | 34.29% |
Annual Asset Resilience Ratio for Anteris Technologies Global Corp (2010–2024)
The table below shows the annual Asset Resilience Ratio data for Anteris Technologies Global Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 33.27% | AU$43.38 Million ≈ $30.69 Million |
AU$130.39 Million ≈ $92.26 Million |
+32.89pp |
| 2022-12-31 | 0.38% | AU$88.76K ≈ $62.80K |
AU$23.48 Million ≈ $16.61 Million |
+0.08pp |
| 2021-12-31 | 0.30% | AU$88.56K ≈ $62.66K |
AU$29.48 Million ≈ $20.86 Million |
-0.58pp |
| 2020-12-31 | 0.88% | AU$111.00K ≈ $78.54K |
AU$12.65 Million ≈ $8.95 Million |
-26.57pp |
| 2019-12-31 | 27.44% | AU$7.14 Million ≈ $5.05 Million |
AU$26.00 Million ≈ $18.40 Million |
+10.46pp |
| 2018-12-31 | 16.99% | AU$5.41 Million ≈ $3.83 Million |
AU$31.86 Million ≈ $22.54 Million |
-1.02pp |
| 2017-12-31 | 18.01% | AU$5.11 Million ≈ $3.61 Million |
AU$28.37 Million ≈ $20.07 Million |
-- |
| 2016-12-31 | 0.00% | AU$0.00 ≈ $0.00 |
AU$28.58 Million ≈ $20.22 Million |
-- |
| 2015-12-31 | 0.00% | AU$0.00 ≈ $0.00 |
AU$26.78 Million ≈ $18.95 Million |
-- |
| 2010-12-31 | 1.98% | AU$291.36K ≈ $206.16K |
AU$14.75 Million ≈ $10.44 Million |
-- |
About Anteris Technologies Global Corp
Anteris Technologies Global Corp., a structural heart company, develops and commercializes minimally invasive medical devices to treat heart valve diseases. It offers the DurAVR transcatheter heart valve system, a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. The company also develops ADAPT anti-calci… Read more